Multiple myeloma is a malignant disorder of plasma cells, characterized by uncontrolled and progressive proliferation of a single clone of plasma cells. The disease leads to progressive morbidity and eventual mortality by lowering resistance to infection and causing significant skeletal destruction with bone pain, pathological fractures and hypercalcemia. Improved understanding of the multiple myeloma biology along with the discovery of novel anti-myeloma agents has led to a better-quality treatment of these patients. However, it still remains an incurable disease for the vast majority of patients, with a median survival 2-3 years. Patients with multiple myeloma frequently develop complications that are reason for early mortality within 60 days of diagnosis. Acute complications such as hyperviscosity syndrome, hypercalcemia, spinal cord compression, early infection, bone disease and renal impairment may be life-threatening. The treatment of these medical emergencies has greatly decreased morbidity and early mortality in patients.

Hyperviscosity syndrome

Hyperviscosity syndrome occurs in cases with high serum paraprotein levels; monoclonal hypergammaglobulinemia is the most common cause, particularly those of IgA or IgG3 type. The reasons for elevated viscosity are increased protein content and large molecular size, abnormal polymerization, and abnormal shape of immunoglobulin molecules (3). Symptomatic hyperviscosity is much more common in Waldenstrom’s macroglobulinemia (10-30%) than it is in myeloma (2-6%). Symptoms of hyperviscosity usually appear when the normal serum viscosity of 1.4 to 1.8 cp reaches 4 to 5 cp, corresponding to a serum immunoglobulin M (IgM) level of at least 3 g/dL, an IgG level of 4 g/dL, and an IgA level of 6 g/dL. Symptoms include bleeding and ocular, neurological and cardiovascular manifestations (mucosal bleeding, blurred vision, headaches, and dyspnea). Immediate therapy of symptomatic hyperviscosity is directed at reduction of blood viscosity by plasmapheresis to control symptoms. Long-term management is directed at control of the underlying disease to prevent production of the monoclonal protein (4).

Hypercalcemia

Patients with multiple myeloma are commonly diagnosed with hypercalcemia. In fact, hypercalcemia is one of the four diagnostic “CRAB” criteria (calcium ele-
complex (as in zoledronic acid) are found (9). Bisphospho-
moieties, either simple (as in pamidronate) or more
nate, small radicals are linked to the carbon, while in se-
chains. In first generation bisphosphonates, like clodro-
been replaced by a carbon that is linked to different side
ators with durable activity. These drugs are pirophospha-
to analogues in which the central oxygen bridge has
hemodialysis may be necessary (8). Administration of
ul narrow the risk of nephrotoxicity, but its ability
tonin has a rapid onset of action and inhibits bone re-
ment is critical for spinal cord compression by a myeloma. Some aut-
the involved level by the epidural myeloma
skeletal related events are not uncommon in pati-
normal spinal involvement of MM (9, 10). Another form
or surgery attempted. Close observation of the neurolo-
hoped in most reported cases with various treatment modalities (12,
hisor recommend radiotherapy combined with high-do-
13). No clear guidelines have been established for spi-
ents with multiple myeloma. Among these, the spine is
one of the commonly involved sites and patholo-
gical fractures of the spinal column are the most com-
rate of development of cord compression and commonly include sensory loss, paresthes-
authors reported that 76% of the patients experien-
ceed an improvement in motor function, 2% deteriora-
te the central oxygen bridge has been replaced by a carbon that is linked to different side
chains. In first generation bisphosphonates, like clodro-
te acute bone metabolism. The most common bisphosphonates used for
hypercacemia in myeloma include zoledronic acid (Zometa) or pamidronate (Aredia) (7, 8). Dental proce-
duces, such as root canal or extraction of teeth, may be
ce of bone destruction (osteonecrosis), so they should be performed before bisp-
phosphonate treatment is started.

Spinal cord compression
Skeletal related events are not uncommon in pati-
events with multiple myeloma. Among these, the spine is
one of the commonly involved sites and patholo-
gical fractures of the spinal column are the most com-
rate of development of cord compression and commonly include sensory loss, paresthes-
ience or depression, myalgia and arthralgia, dry
mouth, polydipsia, anorexia, constipation, abdominal pain, and, eventually, coma. An important first step in
the treatment of hypercalcemia is to replenish fluids, since hypercalcemia increases filtration across the renal
glomerular membrane, interferes with urine concentra-
tion, and causes diuresis and hypovolemia. Therefore,

Additionally, diuretics and corticosteroids are often used to treat the hypercalcemia patient. Forced diuresis
with loop diuretics can help avoid fluid overload and also increase urinary calcium absorption, and cortico-
roids can both decrease calcium absorption from the gut and promote renal excretion. In severe cases and in pa-
te the central oxygen bridge has been replaced by a carbon that is linked to different side
chains. In first generation bisphosphonates, like clodron-
ate, small radicals are linked to the carbon, while in sec-
ond generation bisphosphonates nitrogen containing moieties, either simple (as in pamidronate) or more
complex (as in zoledronic acid) are found (9). Bisphospho-
ates bind avidly to the bone mineral matrix and ther-
fore accumulate in bone at sites of active bone metab-
ism. The most common bisphosphonates used for
hypercacemia in myeloma include zoledronic acid (Zometa) or pamidronate (Aredia) (7, 8). Dental proce-
dures, such as root canal or extraction of teeth, may be
associated with infection or destruction of the jaw (osteonecrosis), so they should be performed before bisp-
phosphonate treatment is started.
is one of the important factors to be considered. If the involved level is the cervical or thoracic level, more attentions should be paid to monitor the neurologic status. Surgical intervention prior to non-surgical treatment should be considered in the cases presented with any deterioration of the neurological status (16).

**Early infection**

It has been reported that up to 10% of patients with MM die of infective causes early, within 60 days of diagnosis. A variety of factors underlie the increased susceptibility of myeloma patients to infectious disease. The immune factors include hypogammaglobulinaemia, impaired lymphocyte function, steroid-related immunosuppression and neutropenia secondary to chemotherapy or marrow infiltration. Physical factors are also important, such as indwelling vascular catheters, impaired mucosal integrity and respiratory compromise because of a combination of pain, vertebral collapse and the use of opiate drugs. The risk of infection is highest in the first 3 months after diagnosis and decreases with response to treatment (17). A recent retrospective analysis of 3107 myeloma patients registered onto UK Medical Research Council (MRC) trials from 1980 to 2002 showed that 10% of patients died within 60 days of trial entry (18) and 45% of these deaths were caused by infection. Blade et al (2001) found in two studies that 7.9% of patients died within 2 months of diagnosis. Streptococcus pneumoniae, Haemophilus influenzae and Escherichia coli are the most frequent causes of infection in myeloma patients (19). Several studies in neutropenic patients suggest that prophylactic antibiotics, such as cotrimoxazole in a small randomized trial in myeloma (20) and levofloxacin in solid tumours (21), may have a role in reducing infection rates but have the potential for leading to antibiotic resistance in the community. Larger studies are required to address the role of prophylactic antibiotics, vaccination strategies and immunoglobulin replacement in multiple myeloma.

**Bone disease**

Bone lesions from multiple myeloma are the primary cause of bone pain, which is one of the most common symptoms of multiple myeloma. Bone lesions result in destruction of the bones in myeloma patients and primarily affecting the spine, pelvis or rib cage. In the majority of patients with myeloma, soft spots develop where the bone structure has been damaged. These can extend from the inner bone marrow to the outside surface of the bone. Soft spots appear as “holes” on a standard bone x-ray and are referred to as osteolytic lesions. These bone lesions weaken the bone, causing pain and increasing the risk of fractures. Bone loss frequently accompanies multiple myeloma, and 85% of patients diagnosed with multiple myeloma have some degree of bone loss (22). Bone destruction by osteolytic lesions is caused by two separate events. Rapid growth of myeloma cells inhibits normal bone-forming cells, damaging bone. In addition, production of substances that activate the cells that resorb bone, called osteoclasts, is increased. Osteoclasts normally break down old or worn out bone and work with bone-forming cells to repair bone. In the case of multiple myeloma, however, the increased activity of osteoclasts causes bone loss with concomitant loss of bone repair and growth from the suppression of bone formation (23). In patients with multiple myeloma, bone resorption by the osteoclasts is increased and exceeds bone reformation. Calcium lost from the bones appears in increasing amounts in the patient’s serum and urine. This increase in bone resorption may result in pain, bone fractures, spinal cord compression, and hypercalcaemia. Long bone fractures are treated by immobilization and radiotherapy that can improve pain and promote healing of the fracture site. The recommended dose is 8 Gy for a single fracture. In case of larger lytic lesions of skeleton, an orthopedic surgeon should be consulted and in some patients a surgery with vertebroplasty or kyphoplasty should be done. Bisphosphonates have a favorable effect in controlling the bone lesions in patients with MM, even in those without bone disease at presentation. The duration of the treatment depends on individual factors such as: achieving remission, expressiveness of bone lesions, renal function (24). It is reasonable to stop the treatment in patients who achieve complete response or a very good partial remission and who do not have active bone disease. It is mandatory to perform a good dental inspection always when bisphosphonate therapy is planned and to perform dental procedures such as root canal or extraction of teeth before these agents are started in order to prevent the most difficult complication-osteonecrosis of the jaw.

**Renal failure**

Renal failure is a frequent and potentially serious complication that occurs in 20-25% of patients with MM at presentation and in nearly 50% of patients during the disease course. In the majority of cases, renal impairment is caused by the accumulation and precipitation of light chains, which form casts in the distal tubules, resulting in renal obstruction. In addition, myeloma light chains are also directly toxic on proximal renal tubules, further adding to renal dysfunction (25). There are several types of apheresis therapy that...
are applicable in MM patients. Plasma exchange (PE) or plasmapheresis involves the separation and removal of the blood cells and other substances from the plasma by centrifugation (based on cell density) or ultrafiltration using large-pore hemofilters (based on molecular size) (26). This method is used to remove pathogenic substances, including paraproteins and inflammatory mediators such as cytokines.

Other factors such as dehydration, hypercalcemia, hyperuricemia, application of nephrotoxic agents for infections, also, contribute to renal failure. Adequate hydration, correction of hypercalcemia and hyperuricemia and antimyeloma therapy should be initiated promptly. For maintenance of a good renal function, patients are advised to stay well-hydrated, to drink enough fluids to produce three liters of urine daily and to avoid nephrotoxic agents including aminoglycosides and non-steroidal anti-inflammatory drugs.

Patients, who have renal failure at presentation, have high level of early fatal outcomes. Supportive care measures are essential and antimyeloma therapy should be initiated as soon as possible. High-dose dexamethasone-based regimens remain the cornerstone in the treatment of these patients, owing to their rapid antimyeloma activity (27). Severe renal impairment and large amount of proteinuria are associated with a lower probability of renal recovery. The addition of novel agents can further increase the rapidity of response and perhaps the probability of restoring renal function.

CONCLUSION

Despite the discovery of novel anti-myeloma agents, multiple myeloma still remains an incurable disease for the vast majority of patients, with a median survival 2-3 years. The incidence of early death within 60 days of diagnosis is 10% due to many acute complications such as hyperviscosity syndrome, hypercalcemia, spinal cord compression, early infection, bone disease and renal impairment. The most common contributors are bacterial infection (50%) and renal failure (28%) according to the United Kingdom’s Medical Research Council (MRC) trials. These complications require specific treatment in addition to therapy directed at the malignant clone that has greatly decreased morbidity and early mortality in patients.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

Licensing

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.

Abbreviations

CRAB — calcium elevation, renal insufficiency, anemia, bone disease
IgG — immunoglobulin G
IgA — immunoglobulin A
IgM — immunoglobulin M
MRI — magnetic resonance imaging
MM — myeloma multiplex
PE — plasma exchange
UK MRC — United Kingdom’s Medical Research Council

Sažetak

AKUTNE KOMPLIKACIJE MULTIPLOG MIJELOMA

Stankovikj Svetlana, Martinova Kata
1 University Clinic of Hematology, Skopje, Macedonia
2 University Children’s Hospital, Skopje, Macedonia

Multiplo mielom je maligno oboljenje plazma čelija, koje karakteriše nekontrolisana i progresivna proliferačija jednog klon plazma čelije. Oboljenje vodi do progresivnog morbiditeta i eventualnog mortaliteta, tako što smanjuje otpor organizma na infekcije i dovodi do značajnih oštećenja na skeletu, praćenog bolom u kostima, patološkim frakturama i hiperkalcemijom. Bolje razumevanje biologije multiplog mieloma zajedno sa otkrićem novih anti-mijelomskih agenasa dovelo je do boljeg lečenja bolesnika. Međutim, multipli mijelom je još uvek neizlečiva bolest za većinu pacijenata, sa srednjom stopom preživljavanja 2-3 godine. Pacijenti koji boluju od multiplog mijeloma često razvijaju komplikacije, koje su razlog njihovog ranijeg mortaliteta u okviru prvih 60 dana od postavljanja dijagnoze. Akutne komplikacije kao što su hiperviskozni sindrom, hiperkalcemija, kompresija kičmeno moždine, rana infekcija, obojenja kostiju i bubrega mogu biti životno ugrozavajuća. Lečenje ovih urgentnih medicinskih stanja uveliko smažuje morbiditet i rani mortalitet kod ovih bolesnika.

Ključne reči: multipli mijelom, hiperviskozni sindrom, hiperkalcemija, kompresija kičmeno moždine.
REFERENCES